Apr 26 |
Three Leading Growth Companies In Australia With Insider Ownership Reaching 27%
|
Mar 27 |
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
|
Mar 26 |
After Almost 4 Years, FDA Says Mesoblast Phase 3 Therapy Data Can Support Resubmission For Serious Complications in Children Following Stem Cell Transplant
|
Mar 26 |
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
|
Mar 13 |
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
|
Mar 10 |
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
|
Mar 3 |
Mesoblast Limited (NASDAQ:MESO) Q2 2024 Earnings Call Transcript
|
Feb 29 |
Mesoblast First Half 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
Feb 28 |
Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
|
Feb 26 |
Mesoblast Financial Results and Corporate Update Webcast
|